On Friday, Novo Nordisk ADR (NYSE: NVO) was -0.77% drop from the session before, before settling in for the closing price of $56.04. A 52-week range for NVO has been $45.05 – $125.62.
During the last 5-year period, the sales growth of Healthcare Sector giant was 21.74%. When this article was written, the company’s average yearly earnings per share was at 21.36%. With a float of $3.37 billion, this company’s outstanding shares have now reached $3.37 billion.
Novo Nordisk ADR (NVO) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Novo Nordisk ADR stocks. The insider ownership of Novo Nordisk ADR is 0.00%, while institutional ownership is 9.18%. The most recent insider transaction that took place on May 30 ’25, was worth 1,972,859.
Novo Nordisk ADR (NVO) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted 6.12 earnings per share (EPS) during the time that was better than consensus figure (set at 5.92) by 0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of 6.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.56% during the next five years compared to 21.74% growth over the previous five years of trading.
Novo Nordisk ADR (NYSE: NVO) Trading Performance Indicators
You can see what Novo Nordisk ADR (NVO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.12. Likewise, its price to free cash flow for the trailing twelve months is 19.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.63, a number that is poised to hit 0.86 in the next quarter and is forecasted to reach 4.15 in one year’s time.
Technical Analysis of Novo Nordisk ADR (NVO)
Looking closely at Novo Nordisk ADR (NYSE: NVO), its last 5-days average volume was 13.9 million, which is a jump from its year-to-date volume of 12.02 million. As of the previous 9 days, the stock’s Stochastic %D was 25.34%.
During the past 100 days, Novo Nordisk ADR’s (NVO) raw stochastic average was set at 29.02%, which indicates a significant decrease from 30.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.34 in the past 14 days, which was lower than the 1.51 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $56.19, while its 200-day Moving Average is $71.94. However, in the short run, Novo Nordisk ADR’s stock first resistance to watch stands at $56.23. Second resistance stands at $56.86. The third major resistance level sits at $57.69. If the price goes on to break the first support level at $54.77, it is likely to go to the next support level at $53.94. Should the price break the second support level, the third support level stands at $53.31.
Novo Nordisk ADR (NYSE: NVO) Key Stats
There are 4,465,000K outstanding shares of the company, which has a market capitalization of 187.19 billion. As of now, sales total 42,108 M while income totals 14,643 M. Its latest quarter income was 11,690 M while its last quarter net income were 4,031 M.
